1
LUNA Michael: [fr] OPTIMISATION DUN CACHE DUN SYSTÈME DE GESTION DE TRAFIC SANS FIL À LAIDE DEN-TÊTE HTTP, [en] WIRELESS TRAFFIC MANAGEMENT SYSTEM CACHE OPTIMIZATION USING HTTP HEADERS. LUNA Michael, FU Yenyun, April 18, 2013: WO/2013/055413 (37 worldwide citation)

[en] Wireless traffic management system cache optimization using HTTP headers is disclosed. In one embodiment, the method can include, for example: storing the web content from a web server as cached elements in a local cache on the mobile device and retrieving the cached elements from the local cac ...


2
FLYGARE John A, GUNZNER TOSTE Janet L, PILLOW Thomas, HOWARD Philip Wilson, MASTERSON Luke: [fr] PYRROLOBENZODIAZÉPINES ET CONJUGUÉS ASSOCIÉS, [en] PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF. SPIROGEN SÀRL, Genentech, YAGER Charlene L, April 18, 2013: WO/2013/055987 (28 worldwide citation)

[en] A conjugate of formula (A): the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R2 is independently selected from H, OH, =0, =CH2, CN, R, OR, =CH-RD, =C(RD)2, 0-S02-R, C02R and COR, and optionally further selected from halo or dihalo; where RD is ind ...


3
ORWAT Michael J, PINTO Donald JP, SMITH II Leon M, SRIVASTAVA Shefali, CORTE James R: [fr] COMPOSÉS TÉTRAHYDROISOQUINOLINES SUBSTITUÉS EN TANT QUINHIBITEURS DU FACTEUR XIA, [en] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS. BRISTOL MYERS SQUIBB COMPANY, LIU Hong, April 18, 2013: WO/2013/055984 (25 worldwide citation)

[en] The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.


4
BOJARSKI Raymond A, FITZ Wolfgang: [fr] PROCÉDÉS ET SYSTÈMES POUR LIDENTIFICATION, LÉVALUATION, LE MODELAGE ET LA RÉPARATION DE DISPARITÉS ANATOMIQUES DANS LE REMPLACEMENT DARTICULATION, [en] METHODS AND SYSTEMS FOR IDENTIFICATION, ASSESSMENT, MODELING, AND REPAIR OF ANATOMICAL DISPARITIES IN JOINT REPLACEMENT. CONFORMIS, SUNSTEIN Bruce D, April 18, 2013: WO/2013/056036 (24 worldwide citation)

[en] Improved systems and methods for deriving anatomical structures from indirect anatomical measurements as well as identifying abnormal, deformed, unusual and/or undesirable anatomical structures, and related improvements in designing and/or selecting patient-adapted (e.g., patient-specific and/o ...


5
MIRELMAN Anat, HAUSDORFF Jeffrey M, GILADI Nir: [fr] RÉALITÉ VIRTUELLE POUR LE DIAGNOSTIC ET/OU LE TRAITEMENT DE TROUBLES DU MOUVEMENT, [en] VIRTUAL REALITY FOR MOVEMENT DISORDER DIAGNOSIS AND/OR TREATMENT. THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, GE EHRLICH, April 18, 2013: WO/2013/054257 (24 worldwide citation)

[en] Methods and/or systems for diagnosing, monitoring and/or treating persons at risk for falling and/or other pathological conditions. In an exemplary embodiment of the invention, people are diagnosed before they actually start falling. Optionally, the diagnosis includes trying out and identifying ...


6
ORWAT Michael J, PINTO Donald JP, SMITH II Leon M, SRIVASTAVA Shefali: [fr] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE SUBSTITUÉS EN TANT QUINHIBITEURS DU FACTEUR XIA, [en] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS. BRISTOL MYERS SQUIBB COMPANY, LIU Hong, April 18, 2013: WO/2013/056034 (23 worldwide citation)

[en] The present invention provides compounds of Formula (I) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.


7
ORWAT Michael J, PINTO Donald JP, SMITH II Leon M, SRIVASTAVA Shefali: [fr] COMPOSÉS DE TÉTRAHYDROISOQUINOLÉINE SUBSTITUÉS COMME INHIBITEURS DU FACTEUR XIA, [en] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS. BRISTOL MYERS SQUIBB COMPANY, LIU Hong, April 18, 2013: WO/2013/056060 (20 worldwide citation)

[en] The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.


8
HOWARD Philip Wilson, TIBERGHIEN Arnaud, JEFFREY Scott, BURKE Patrick: [fr] PYRROLOBENZODIAZÉPINES, [en] PYRROLOBENZODIAZEPINES. SPIROGEN SÀRL, SEATTLE GENETICS, WATSON Robert, April 18, 2013: WO/2013/053873 (20 worldwide citation)

[en] A compound with the formula (I), wherein: R2 is of formula (II), where X is selected from the group comprising: OH, SH, CO2H, COH, N=C=O, NHNH2, CONHNH2, formula (A), formula (B), NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl; RC1, RC2 and RC3 are independently selecte ...


9
FAHAM Malek: [fr] DÉTERMINATION DE LA SENSIBILITÉ DE PATIENTS ATTEINTS DUNE MALADIE AUTO-IMMUNE AU TRAITEMENT SOUS ARMM, [en] DETERMINING RESPONSIVENESS OF AUTOIMMUNE PATIENTS TO DMARD TREATMENT. FAHAM Malek, SEQUENTA, SEIDEL Jeffrey J, April 18, 2013: WO/2013/055595 (20 worldwide citation)

[en] The invention is directed to a method of screening patients suffering from an autoimmune disease for responsiveness to treatment with a disease modifying anti-rheumatic drug, or DMARD. In some embodiments the method of the invention comprises the steps of (a) measuring an IgH clonotype profile ...


10
HOWARD Philip Wilson: [fr] PYRROLOBENZODIAZÉPINES, [en] PYRROLOBENZODIAZEPINES. SPIROGEN SÀRL, WATSON Robert, April 18, 2013: WO/2013/053871 (19 worldwide citation)

[en] A compound with the formula I: wherein: R2 is of formula II: where A is a C5-7 aryl group, X is selected from the group comprising: NHNH2, CONHNH2, formula III, formula IV, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and -Z-(CH2)n-, where Z is selected from a sing ...